Trial · NCT01992653
Adverse events1,896
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
1 to 20 of 1,896
Download this page as JSON| Type | Event | Organ system | Group | Affected | At risk | Events |
|---|---|---|---|---|---|---|
| other | ANAEMIA | Blood and lymphatic system disorders | Polatuzumab Vedotin (1.0mg) + R-CHP | 0 | 3 | 0 |
| other | ANAEMIA | Blood and lymphatic system disorders | Polatuzumab Vedotin (1.4mg) + R-CHP | 0 | 3 | 0 |
| other | ANAEMIA | Blood and lymphatic system disorders | Polatuzumab Vedotin (1.8mg) + R-CHP | 0 | 6 | 0 |
| other | ANAEMIA | Blood and lymphatic system disorders | Polatuzumab Vedotin (2.4mg) + R-CHP | 0 | 1 | 0 |
| other | ANAEMIA | Blood and lymphatic system disorders | Polatuzumab Vedotin (1.4mg) + G-CHP | 3 | 6 | 4 |
| other | ANAEMIA | Blood and lymphatic system disorders | Polatuzumab Vedotin (1.8mg) + G-CHP | 2 | 6 | 5 |
| other | ANAEMIA | Blood and lymphatic system disorders | Expansion: Polatuzumab Vedotin (1.8mg) + R-CHP | 14 | 40 | 24 |
| other | ANAEMIA | Blood and lymphatic system disorders | Expansion: Polatuzumab Vedotin (1.8mg) + G-CHP | 3 | 17 | 7 |
| other | FEBRILE NEUTROPENIA | Blood and lymphatic system disorders | Polatuzumab Vedotin (1.0mg) + R-CHP | 0 | 3 | 0 |
| other | FEBRILE NEUTROPENIA | Blood and lymphatic system disorders | Polatuzumab Vedotin (1.4mg) + R-CHP | 0 | 3 | 0 |
| other | FEBRILE NEUTROPENIA | Blood and lymphatic system disorders | Polatuzumab Vedotin (1.8mg) + R-CHP | 0 | 6 | 0 |
| other | FEBRILE NEUTROPENIA | Blood and lymphatic system disorders | Polatuzumab Vedotin (2.4mg) + R-CHP | 0 | 1 | 0 |
| other | FEBRILE NEUTROPENIA | Blood and lymphatic system disorders | Polatuzumab Vedotin (1.4mg) + G-CHP | 0 | 6 | 0 |
| other | FEBRILE NEUTROPENIA | Blood and lymphatic system disorders | Polatuzumab Vedotin (1.8mg) + G-CHP | 0 | 6 | 0 |
| other | FEBRILE NEUTROPENIA | Blood and lymphatic system disorders | Expansion: Polatuzumab Vedotin (1.8mg) + R-CHP | 3 | 40 | 3 |
| other | FEBRILE NEUTROPENIA | Blood and lymphatic system disorders | Expansion: Polatuzumab Vedotin (1.8mg) + G-CHP | 1 | 17 | 1 |
| other | LEUKOCYTOSIS | Blood and lymphatic system disorders | Polatuzumab Vedotin (1.0mg) + R-CHP | 0 | 3 | 0 |
| other | LEUKOCYTOSIS | Blood and lymphatic system disorders | Polatuzumab Vedotin (1.4mg) + R-CHP | 0 | 3 | 0 |
| other | LEUKOCYTOSIS | Blood and lymphatic system disorders | Polatuzumab Vedotin (1.8mg) + R-CHP | 0 | 6 | 0 |
| other | LEUKOCYTOSIS | Blood and lymphatic system disorders | Polatuzumab Vedotin (2.4mg) + R-CHP | 0 | 1 | 0 |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT01992653/events